All members of the T2EVOLVE consortium are innovators and pioneers in the field of immunotherapy, highly committed to bridge the existing gaps between research and clinical application in Europe and make the EU lead the promising engineered T-cell therapy movement.
Leadership & Partners
The T2EVOLVE consortium is coordinated by the Universitätsklinikum Würzburg and Servier. Our multidisciplinary consortium is made up of 27 European partners from nine different countries.
Partners include university and non-university research facilities, pharmaceutical and biotechnology companies, SMEs as well as regulatory authorities and patients and professional associations.